List of Baxdela drug patents
Baxdela is owned by Melinta.
Baxdela contains Delafloxacin Meglumine.
Baxdela has a total of 13 drug patents out of which 0 drug patents have expired.
Baxdela was authorised for market use on 19 June, 2017.
Baxdela is available in tablet;oral dosage forms.
Baxdela can be used as treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults.
Drug patent challenges can be filed against Baxdela from June, 2026.
The generics of Baxdela are possible to be released after 27 February, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9539250 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
| US8273892 | MELINTA | Salt and crystalline forms thereof of a drug |
Aug, 2026
(3 years from now) | |
| US8871938 | MELINTA | Process for making quinolone compounds |
Sep, 2029
(6 years from now) | |
| USRE46617 | MELINTA | Process for making quinolone compounds |
Dec, 2029
(6 years from now) | |
| US7728143 | MELINTA | Salt and crystalline forms thereof of a drug |
Jun, 2031
(8 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8969569 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
| US8648093 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2025
(2 years from now) | |
| US8252813 | MELINTA | Salt and crystalline forms thereof of a drug |
Oct, 2026
(3 years from now) | |
| US8410077 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9200088 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US7635773 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9750822 | MELINTA | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9493582 | MELINTA | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jun 19, 2022 |
| New Indication (I) | Oct 24, 2022 |
| Generating Antibiotic Incentives Now (GAIN) | Jun 19, 2027 |
Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 19 June, 2017
Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic